H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

On May 28, Oren Livnat, an analyst from H.C. Wainwright initiated coverage of Trevi Therapeutics, Inc. (NASDAQ:TRVI) with a Buy rating and a $21 price target.

Keep Reading →